13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04291456January 31, 202018/11/2019Minocycline in MS: Confirmation of BenefitOpen-Label Trial of Minocycline in Early Multiple Sclerosis: Confirmation of Treatment BenefitMultiple Sclerosis;Clinically Isolated SyndromeDrug: Minocycline 100mgUniversity of CalgaryHotchkiss Brain Institute, University of CalgaryRecruiting18 Years60 YearsAll148Phase 3Canada
2NCT01073813February 201022/2/2010Neuroprotection and Repair in Optic NeuritisDeveloping Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON)Multiple Sclerosis;Optic NeuritisDrug: MinocyclineUniversity of CalgaryNeuroscience CanadaTerminated18 Years60 YearsBoth6Phase 2Canada
3NCT00666887January 200923/4/2008Minocycline in Clinically Isolated Syndromes (CIS)A Phase III Double-blind, Randomized, Placebo-controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS)Clinically Isolated Syndromes;Early Single Relapse of Multiple SclerosisDrug: Minocycline;Drug: PlaceboDr. Luanne MetzMultiple Sclerosis Society of CanadaCompleted18 Years60 YearsAll142Phase 3Canada
4NCT01134627February 200628/5/2010Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDrug: Minocycline;Drug: PlaceboMerck KGaANULLTerminated18 Years55 YearsAll305Phase 2Denmark
5EUCTR2005-004289-18-FI26/01/200607/11/2005A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) Relapse Remitting Multiple Sclerosis
MedDRA version: 8.0Level: PTClassification code 10063399
Product Name: Minocycline 100 mg Film-coated Tablets
INN or Proposed INN: Minocycline Hydrochloride
Merck ABNULLNot RecruitingFemale: yes
Male: yes
320Finland;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2005-004289-18-SE04/01/200610/11/2005A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) Relapse Remitting Multiple Sclerosis
MedDRA version: 8.0Level: PTClassification code 10063399
Product Name: Minocycline 100 mg Film-coated Tablets
INN or Proposed INN: Minocycline Hydrochloride
Merck ABNULLNot RecruitingFemale: yes
Male: yes
320Finland;Sweden
7EUCTR2005-004289-18-DK19/12/200528/11/2005A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline) Relapse Remitting Multiple Sclerosis
MedDRA version: 8.0Level: PTClassification code 10063399
Product Name: Minocycline 100 mg Film-coated Tablets
INN or Proposed INN: Minocycline Hydrochloride
E. Merck ABNULLNot RecruitingFemale: yes
Male: yes
320Finland;Denmark;Sweden
8NCT00203112June 200413/9/2005Safety and Efficacy Study of Copaxone Administered in Combination With MinocyclineA Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA).Relapse Remitting Multiple SclerosisDrug: glatiramer acetate with minocycline;Drug: Glatiramer acetate with placeboTeva Pharmaceutical IndustriesNULLCompleted18 Years50 YearsBoth44Phase 2Canada